D
Dan Peer
Researcher at Tel Aviv University
Publications - 207
Citations - 18194
Dan Peer is an academic researcher from Tel Aviv University. The author has contributed to research in topics: RNA interference & Gene silencing. The author has an hindex of 49, co-authored 190 publications receiving 14827 citations. Previous affiliations of Dan Peer include KAIST & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Nanocarriers as an emerging platform for cancer therapy
Dan Peer,Jeffrey M. Karp,Jeffrey M. Karp,Seungpyo Hong,Omid C. Farokhzad,Rimona Margalit,Robert Langer +6 more
TL;DR: The arsenal of nanocarriers and molecules available for selective tumour targeting, and the challenges in cancer treatment are detailed and emphasized.
Journal ArticleDOI
Progress and challenges towards targeted delivery of cancer therapeutics.
TL;DR: The principles behind targeted delivery approaches are reviewed to determine potential reasons for their limited clinical translation and success and criteria and considerations that must be taken into account for the development of novel actively targeted NCs are proposed.
Journal ArticleDOI
Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target.
TL;DR: This study reveals CyD1 to be a potential anti-inflammatory target, and suggests that the application of similar modes of targeting by siRNA may be feasible in other therapeutic settings.
Journal ArticleDOI
Nanoparticle hydrophobicity dictates immune response.
Daniel F. Moyano,Meir Goldsmith,David J. Solfiell,Dalit Landesman-Milo,Oscar R. Miranda,Dan Peer,Vincent M. Rotello +6 more
TL;DR: Empirically engineered gold nanoparticles were used to determine the sole effect of hydrophobicity on the immune response of splenocytes, with an essentially linear increase in immune activity with the increase in hydrophOBicity observed in vitro.
Journal ArticleDOI
The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation.
TL;DR: It is shown that activation of TLR4 might serve as the underlying mechanism for induction of an immune response when (+)NPs are used, and a careful attention must be made when different types of (+) NPs are being developed as nanotherapeutics.